After posting midphase data, Rezolute banks $130M to take treatment for rare disease into pivotal trialnews2022-05-02T11:40:51+00:00May 2nd, 2022|FierceBiotech|
Seeing green: Breakthrough Properties raises $3B to build in biotechnews2022-04-29T20:19:30+00:00April 29th, 2022|FierceBiotech|
Human testing for Praxis’ lead epilepsy drug held up after FDA clinical holdnews2022-04-29T16:11:58+00:00April 29th, 2022|FierceBiotech|
AstraZeneca will have to wait a little longer for fruit from $3.5B Ionis ATTR partnershipnews2022-04-29T16:04:19+00:00April 29th, 2022|FierceBiotech|
AbbVie’s cystic fibrosis long-game doesn’t pay off, as Galapagos med fails in triple combonews2022-04-29T15:02:53+00:00April 29th, 2022|FierceBiotech|
While BMS waits for TYK2 inhibitor’s psoriasis nod, a new path potentially clears in lupusnews2022-04-29T14:29:49+00:00April 29th, 2022|FierceBiotech|
Genocea’s Atlas no longer holding up sky, as biotech moves for sell offnews2022-04-29T14:00:40+00:00April 29th, 2022|FierceBiotech|
Finch’s C. diff drug cleared of FDA hold, but loose ends leave timing for phase 3 restart unclearnews2022-04-29T12:46:13+00:00April 29th, 2022|FierceBiotech|
AstraZeneca kicks off work on 1,500-person R&D center in Kendall Square news2022-04-29T08:54:48+00:00April 29th, 2022|FierceBiotech|
‘Serious missteps’: All Blue makes case for $773M Zymeworks buyout in wake of flagging stocknews2022-04-29T07:54:15+00:00April 29th, 2022|FierceBiotech|
